P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES
Main Authors: | C. M. KHOO, X. SONG, Q. WU, G. F. COX |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846172.64321.0a |
Similar Items
-
Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
by: Weitz IC
Published: (2023-03-01) -
P791: COMMON VARIANTS IN COMPLEMENT PROTEINS, C3 AND CR1, ENHANCE COMPLEMENT ATTACK ON PNH ERYTHROCYTES AND INCREASE RISK FOR EXTRAVASCULAR HAEMOLYSIS
by: A. J. Baral, et al.
Published: (2022-06-01) -
Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
by: Bindon, C, et al.
Published: (1988) -
Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
by: Cobbold, S, et al.
Published: (1990) -
Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
by: Cobbold, S, et al.
Published: (1990)